Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.78 |
| ▸ | CNR2 | P34972 | 10/20 | 0.78 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621799 | 0.88 | CNR1 (1.00) | CNR1CNR2NT5EKIF11 | |
| SCHEMBL1621351 | 0.87 | CNR1 (0.81) | CNR1CNR2CACNA1HNT5EKIF11 | |
| SCHEMBL1620314 | 0.85 | CNR1 (0.73) | CNR1CNR2CACNA1HNT5EKIF11 | |
| SCHEMBL1619279 | 0.83 | CNR1 (0.70) | CNR1CNR2CACNA1HCACNA1CNT5E | |
| SCHEMBL1621214 | 0.82 | CNR1 (0.91) | CNR1CNR2CACNA1H | |
| SCHEMBL1620675 | 0.82 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL1619028 | 0.81 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL1621023 | 0.80 | CNR2 (0.87) | CNR1CNR2 | |
| SCHEMBL1621086 | 0.80 | CNR1 (0.85) | CNR1CNR2 | |
| SCHEMBL1621369 | 0.78 | CNR1 (0.76) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| EP-2203427-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | Abbott Healthcare Products B.V. (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037244-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | disclosed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | disclosed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885CACNA1H 1182/4885 |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885CACNA1H 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.